Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MetAP2 |
| Gene Name: | METAP2 |
| Protein Full Name: | Methionine aminopeptidase 2 |
| Alias: | AMPM2; EC 3.4.11.18; Initiation factor 2-associated 67 kDa glycoprotein; MAP2; MetAP 2; Methionyl aminopeptidase 2; MNPEP; P67; P67eIF2; Peptidase M 2 |
| Mass (Da): | 52892 |
| Number AA: | 478 |
| UniProt ID: | P50579 |
| Locus ID: | 10988 |
| COSMIC ID: | METAP2 |
| Gene location on chromosome: | 12q22 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.3 |
| Normal role description: | METAP2 is a methionyl aminopeptidase that binds two cobalt- or manganese ions. It plays an important role in the regulation of protein synthesis and in the proliferation of endothelial- and certain tumour cells, and functions by both protecting the α-subunit of Eukaryotic initiation factor 2 from inhibition by phosphorylation, and by removing the N-terminal methionine residue from newly synthesized peptides. Over-expression of the gene has been linked to various forms of cancer and it has been hypothesized to be functioning as an oncogene. Inhibition of METAP2 has been shown to activate p53-mediated cell-cycle arrest. |